Product NDC: | 0179-1427 |
Proprietary Name: | ERY-TAB |
Non Proprietary Name: | ERYTHROMYCIN |
Active Ingredient(s): | 333 mg/1 & nbsp; ERYTHROMYCIN |
Administration Route(s): | ORAL |
Dosage Form(s): | TABLET, DELAYED RELEASE |
Coding System: | National Drug Codes(NDC) |
Product NDC: | 0179-1427 |
Labeler Name: | KAISER FOUNDATION HOSPITALS |
Product Type: | HUMAN PRESCRIPTION DRUG |
FDA Application Number: | ANDA062298 |
Marketing Category: | ANDA |
Start Marketing Date: | 20090828 |
Package NDC: | 0179-1427-88 |
Package Description: | 600 TABLET, DELAYED RELEASE in 1 BOTTLE (0179-1427-88) |
NDC Code | 0179-1427-88 |
Proprietary Name | ERY-TAB |
Package Description | 600 TABLET, DELAYED RELEASE in 1 BOTTLE (0179-1427-88) |
Product NDC | 0179-1427 |
Product Type Name | HUMAN PRESCRIPTION DRUG |
Non Proprietary Name | ERYTHROMYCIN |
Dosage Form Name | TABLET, DELAYED RELEASE |
Route Name | ORAL |
Start Marketing Date | 20090828 |
Marketing Category Name | ANDA |
Labeler Name | KAISER FOUNDATION HOSPITALS |
Substance Name | ERYTHROMYCIN |
Strength Number | 333 |
Strength Unit | mg/1 |
Pharmaceutical Classes | Decreased Sebaceous Gland Activity [PE],Macrolide [EPC],Macrolide Antimicrobial [EPC],Macrolides [Chemical/Ingredient] |